Biotheranostics’ Breast Cancer Index IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors
Biotheranostics, Inc. announces the publication of results from the IDEAL study in Clinical Cancer Research which reports novel findings of its Breast Cancer Index (BCI) and predictive evidence in patients treated with aromatase inhibitors.
Findings from the study further strengthen the clinical evidence for the Breast Cancer Index as the endocrine response biomarker that identifies patients with improved outcomes as well as those who are not likely to benefit from longer durations of endocrine treatment.